An observational study in Multiple Sclerosis, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-26.
Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 289 studies in Multiple Sclerosis with a site in Italy — 59 open to participants now, 90 under way, 13 of them phase 3. Multiple Sclerosis · Italy.
Among the 289 studies in Multiple Sclerosis with a site in Italy, this one is the 17th largest by planned enrollment of the 59 observational ones that give a count, is one of 16 that started in 2024, is one of 59 observational ones, reaches primary completion later than 35 of the 89 other live ones, and was the 255th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →59 of the 289 studies in Multiple Sclerosis with a site in Italy are open now. Recruiting first, the newest first:
University of Catania · Sites in Italy
Ages 20–40 · Healthy volunteers
Ciceri Fabio · Sites in Italy
Ages 18+
Azienda Usl di Bologna · Sites in Italy
Ages 18–65
Sanofi · Sites in Italy, United States, Belgium and 4 more countries
Ages 18–60
Novartis Pharmaceuticals · Sites in Italy, United States, Argentina and 33 more countries
Ages 18–65
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
289 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 40 · Phase 3 66 · Phase 4 19
First in 1999; this study’s year is marked. 16 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 100 across 972 observational studies indexed under Multiple Sclerosis.
Median enrollment 115 across the 230 interventional studies, 214 across the 59 observational. Of the 164 that completed or were terminated, 77 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 289 have an industry lead sponsor. The 10 most frequent:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 953 studies on the registry; 541 are open to participants now.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS has 5 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
17 of the studies in Multiple Sclerosis with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
| NCT05748015Istituti Clinici Scientifici Maugeri SpADefinition of Autonomic Nervous System Involvement in Patients With Multiple Sclerosis | 2026-11-30 |
| NCT07502066IRCCS San Camillo, Venezia, ItalyClinical Efficacy of a telerehabilItation Protocol, for the Improvement of Balance in Degenerative Neurological Diseases | 2026-12 |
| NCT07616050Marta MondelliniEvaluation of the Impact of Virtual Park on Training Motivation in Adult Patients | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 289 studies in Multiple Sclerosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to evaluate the presence of adverse childhood experiences (ACE) in patients with Multiple Sclerosis. The main questions it aims to answer are:
Multiple sclerosis is a chronic inflammatory, demyelinating, and neurodegenerative disease of the central nervous system, typically affecting young adults. Its etiopathogenesis is multifactorial, with the interaction of genetic susceptibility and environmental risk factors. Among these, childhood trauma and other forms of adverse childhood experiences (ACE) such as divorce or parental loss have been called out as possible risk factors in the development of MS and disease relapse.
Adverse Childhood Experiences are a heterogeneous group of negative experiences occurred during childhood, that may have an unfavorable impact on the later course of life in terms of physical and mental health. These effects may be related to changes in the prefrontal, limbic, and hypothalamic-pituitary-adrenal areas and may cause repercussions on the immune system, as documented on experimental models of autoimmune encephalitis. In addition to that, a history of ACE has been associated with the development of poor coping strategies during adulthood . Since multiple sclerosis represents a chronic and progressive disease, the kind of coping strategies developed from childhood may affect how the patient perceives the disease and may affect his or her adherence to treatment.
To date, data on the prevalence of traumatic events during childhood in patients with Multiple Sclerosis are limited to a few studies, while the impact of such events on how the patient copes with the diagnosis of disease and acceptance of therapy. has not yet been explored.
This study represents a preliminary analysis of the impact of ACE in a cohort of multiple sclerosis patients and aims to evaluate how early negative life experiences may affect patients' coping strategies towards the disease and their compliance to treatment.
500 Multiple Sclerosis patients referred to the Multiple Sclerosis Center of the Agostino Gemelli IRCCS University Polyclinic
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients diagnosed with multiple sclerosis between 2014 and 2024, referring to the Multiple Sclerosis Center of the Agostino Gemelli IRCCS
To assess the prevalence of ACE in a cohort of patients with relapsing-remitting multiple sclerosis
The patients will answer to questionnaires provided on an electronic tablet during regular follow up neurological visits. The presence of adverse childhood experiences will be explored through the completion of a specific questionnaire: Childhood Trauma Questionnaire (CTQ): score 0-28 Higher scores mean higher probability to have experienced ACE
Time frame: At enrollement
To assess the prevalence of ACE in a cohort of patients with relapsing-remitting multiple sclerosis
The patients will answer to questionnaires provided on an electronic tablet during regular follow up neurological visits. The presence of dysfunctional parenting during childhood will be explored through the completion of the Measure of Parental Style (MOPS) questionnaire (score 0-28): higher scores mean higher probability to have experienced dysfunctional parenting, leading to ACE
Time frame: At enrollement
To correlate the impact of ACE on quality of life and general distress
Quality of life and general distress will be assessed through Brief Symptom Checklist (BSC): score 0-53, higher scores mean higher distress and worse quality of life
Time frame: 1 year
To correlate the impact of ACE on how the patient perceives and copes with the disease
Quality of life and physician-patient relationship satisfaction will be assessed through patient reported outcomes
Time frame: 1 year
To correlate the impact of ACE on treatment adherence
Treatment satisfaction and compliance will be assessed through patient reported otcomes
Time frame: 1 year
To correlate the impact of ACE on disease treatment
To explore treatment satisfaction through the analysis of the number of treatment switches for poor tolerability
Time frame: 1 year
Plan to share: No
Started Jan 2024 (actual). Primary completion is estimated for Dec 2025, 23 months after the start.
Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 23 months is below that.
Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS →